Calando, Others Miss 2010 Partnering Guidance as Industry Takes Sober View of RNAi | GenomeWeb

This article has been updated to clarify the status of Alnylam Pharmaceuticals' partnering efforts.

By Doug Macron

Arrowhead Research announced last month that its Calando Pharmaceuticals subsidiary would not meet its goal of forging an industry partnership before the end of 2010, making it one of several RNAi drug shops that failed to fulfill promises to secure partnerships last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.